{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:07:09Z","timestamp":1791900429793,"version":"4.3.4"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["neurology.org"],"crossmark-restriction":true},"short-container-title":["Neurology"],"published-print":{"date-parts":[[1996,9]]},"DOI":"10.1212\/wnl.47.3.678","type":"journal-article","created":{"date-parts":[[2012,5,13]],"date-time":"2012-05-13T09:23:00Z","timestamp":1336900980000},"page":"678-683","update-policy":"https:\/\/doi.org\/10.1212\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":212,"title":["Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome"],"prefix":"10.1212","volume":"47","author":[{"given":"P. G.","family":"Bain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Motomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Newsom-Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. A.","family":"Misbah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. M.","family":"Chapel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. L.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199307013290101"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199201023260101"},{"key":"e_1_3_1_4_2","first-page":"2","volume":"40","year":"1990","unstructured":"Van Doorn PA, Brand A, Strengers PFW, Meulstee J, Vermeulen M. High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled crossover study. Neurology 1990;40:209-212.","journal-title":"Neurology"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199201023260101"},{"key":"e_1_3_1_6_2","first-page":"2","volume":"2","year":"1981","unstructured":"Lang B, Newsom-Davis J, Wray D, Vincent A, Murray NMF. Autoimmune aetiology for myasthenic (Eaton-Lambert) syndrome. Lancet 1981;2:224-226.","journal-title":"Lancet"},{"key":"e_1_3_1_7_2","first-page":"1","volume":"183","year":"1971","unstructured":"Lambert EH, Elmqvist D. Quantal components of end-plate potentials in the myasthenic syndrome. Ann NY Acad Sci 1971;183:183-199.","journal-title":"Ann NY Acad Sci"},{"key":"e_1_3_1_8_2","first-page":"6","volume":"5","year":"1982","unstructured":"Fukunaga H, Engel AG, Osame M, Lambert EH. Paucity and disorganisation of presynaptic membrane active zones in the Lambert-Eaton myasthenic syndrome. Muscle Nerve 1982;5:686-697.","journal-title":"Muscle Nerve"},{"key":"e_1_3_1_9_2","first-page":"3","volume":"344","year":"1983","unstructured":"Lang B, Newsom-Davis J, Prior C, Wray D. Antibodies to motor nerve terminals: an electrophysiological study of a human myasthenic syndrome transferred to mouse. J Physiol (Lond) 1983;344:335-345.","journal-title":"J Physiol (Lond)"},{"key":"e_1_3_1_10_2","first-page":"7","volume":"80","year":"1983","unstructured":"Fukunaga H, Engel AG, Lang B, Newsom-Davis J, Vincent A. Passive transfer of Lambert-Eaton myasthenic syndrome with IgG from man to mouse depletes the presynaptic membrane active zones. Proc Natl Acad Sci USA 1983;80:7636-7640.","journal-title":"Proc Natl Acad Sci USA"},{"key":"e_1_3_1_11_2","first-page":"2","volume":"390","year":"1987","unstructured":"Lang B, Newsom-Davis J, Peers C, Prior C, Wray DW. The effect of myasthenic syndrome antibody on presynaptic calcium-channels in the mouse. J Physiol (Lond) 1987;390:257-270.","journal-title":"J Physiol (Lond)"},{"key":"e_1_3_1_12_2","first-page":"8","volume":"58","year":"1995","unstructured":"Motomura M, Johnston I, Lang B, Vincent A, Newsom-Davis J. An improved diagnostic assay for Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 1995;58:85-87.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"e_1_3_1_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199501053320101"},{"key":"e_1_3_1_14_2","first-page":"5","volume":"111","year":"1988","unstructured":"O'Neill JH, Murray NM, Newsom-Davis J. The Lambert-Eaton myasthenic syndrome. A review of 50 cases. Brain 1988;111:577-596.","journal-title":"Brain"},{"key":"e_1_3_1_15_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.40.1.1"},{"key":"e_1_3_1_16_2","first-page":"7","volume":"317","year":"1985","unstructured":"Roberts A, Perera S, Lang B, Vincent A, Newsom-Davis J. Paraneoplastic myasthenic syndrome IgG inhibits sup 45 Ca sup 2+ flux in a human small cell carcinoma line. Nature 1985;317:737-739.","journal-title":"Nature"},{"key":"e_1_3_1_17_2","first-page":"4","volume":"34","year":"1984","unstructured":"Newsom-Davis J, Murray NMF. Plasma exchange and immunosuppressive drug treatment in the Lambert-Eaton myasthenic syndrome. Neurology 1984;34:480-485.","journal-title":"Neurology"},{"key":"e_1_3_1_18_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.42.1.1"},{"key":"e_1_3_1_19_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1986.00520010009006"},{"key":"e_1_3_1_20_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.57.Suppl.1"},{"key":"e_1_3_1_21_2","first-page":"3","volume":"53","year":"1990","unstructured":"Wiles CM, Karni Y, Nicklin J. Laboratory testing of muscle function in the management of neuromuscular disease. J Neurol Neurosurg Psychiatry 1990;53:384-387.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"e_1_3_1_22_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.55.Suppl.8"},{"key":"e_1_3_1_23_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.46.1.1"},{"key":"e_1_3_1_24_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.54.1.1"},{"key":"e_1_3_1_25_2","unstructured":"Rowland M Tozer TN. Clinical pharmacokinetics: concepts and applications. Philadelphia: Lea & Febiger 1980;288-291."},{"key":"e_1_3_1_26_2","first-page":"2","volume":"9","year":"1993","unstructured":"Misbah SA, Chapel HM. Adverse effects of intravenous immunoglobulin. Drug Saf 1993;9:254-262.","journal-title":"Drug Saf"},{"key":"e_1_3_1_27_2","first-page":"2","volume":"121","year":"1994","unstructured":"Sekul EA, Cupler EJ, Dalakas MC. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med 1994;121:259-262.","journal-title":"Ann Intern Med"},{"key":"e_1_3_1_28_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199407073310101"},{"key":"e_1_3_1_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00918789"}],"container-title":["Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.neurology.org\/doi\/pdfdirect\/10.1212\/WNL.47.3.678","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T06:14:20Z","timestamp":1711520060000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.neurology.org\/doi\/10.1212\/WNL.47.3.678"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1996,9]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1996,9]]}},"alternative-id":["10.1212\/WNL.47.3.678"],"URL":"https:\/\/doi.org\/10.1212\/wnl.47.3.678","relation":{},"ISSN":["0028-3878","1526-632X"],"issn-type":[{"value":"0028-3878","type":"print"},{"value":"1526-632X","type":"electronic"}],"subject":[],"published":{"date-parts":[[1996,9]]}}}